Enhanced therapeutic efficacy of dual JAK2/ERK1/2 inhibition in Jak2V617F and MPLW515L MPN models is confirmed with the alternative ERK1/2 inhibitor MK-8353. This evidence concerns the gene MAPK3 and myeloproliferative neoplasm.